David Lathbury

Dr Lathbury has over 25 years of industrial experience in the fine chemical, agrochemical, and pharmaceutical fields. Over the last 20 years he has worked in the pharmaceutical arena at SmithKline Beecham, and at AstraZeneca, where he was Head of Process Chemistry. Most recently he was Vice President of Chemical Development at Albany Molecular Research in Syracuse, New York. During his extensive career, David has worked on four marketed drugs, including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of “Iressa” and “Crestor”. He is author or co-author on 30 publications and patents. David is a Fellow of the Royal Society of Chemistry and is a visiting Professor at Bristol University.